{
    "id": 6424,
    "fullName": "TGFB1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "TGFB1 over exp indicates an over expression of the Tgfb1 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 7040,
        "geneSymbol": "TGFB1",
        "terms": [
            "TGFB1",
            "CED",
            "DPD1",
            "IBDIMDE",
            "LAP",
            "TGF-beta1",
            "TGFB",
            "TGFbeta"
        ]
    },
    "variant": "over exp",
    "createDate": "05/19/2015",
    "updateDate": "05/02/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2200,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AP 11014 inhibited Tgfb1 secretion, proliferation, and migration in colon cancer cells over expressing Tgfb1 (J Clin Oncol July 2004 vol. 22 no. 14_suppl 3132).",
            "molecularProfile": {
                "id": 6274,
                "profileName": "TGFB1 over exp"
            },
            "therapy": {
                "id": 2706,
                "therapyName": "AP 11014",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2757,
                    "pubMedId": null,
                    "title": "The TGF-beta1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: Preclinical studies",
                    "url": "http://meeting.ascopubs.org/cgi/content/short/22/14_suppl/3132"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2201,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AP 11014 inhibited Tgfb1 secretion, proliferation, and migration in prostate cancer cells over expressing Tgfb1 (J Clin Oncol: July 2004 vol. 22 no. 14_suppl 3132).",
            "molecularProfile": {
                "id": 6274,
                "profileName": "TGFB1 over exp"
            },
            "therapy": {
                "id": 2706,
                "therapyName": "AP 11014",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2757,
                    "pubMedId": null,
                    "title": "The TGF-beta1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: Preclinical studies",
                    "url": "http://meeting.ascopubs.org/cgi/content/short/22/14_suppl/3132"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2261,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SM16 promoted an immune response and inhibited growth of mouse models of mesothelioma over expressing TGFB1 (PMID: 17332368).",
            "molecularProfile": {
                "id": 6274,
                "profileName": "TGFB1 over exp"
            },
            "therapy": {
                "id": 2754,
                "therapyName": "SM16",
                "synonyms": null
            },
            "indication": {
                "id": 1790,
                "name": "malignant mesothelioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2877,
                    "pubMedId": 17332368,
                    "title": "A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17332368"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2199,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AP 11014 inhibited Tgfb1 secretion, proliferation, and migration in NSCLC cells over expressing Tgfb1 (J Clin Oncol: July 2004 vol. 22 no. 14_suppl 3132).",
            "molecularProfile": {
                "id": 6274,
                "profileName": "TGFB1 over exp"
            },
            "therapy": {
                "id": 2706,
                "therapyName": "AP 11014",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2757,
                    "pubMedId": null,
                    "title": "The TGF-beta1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: Preclinical studies",
                    "url": "http://meeting.ascopubs.org/cgi/content/short/22/14_suppl/3132"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2208,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SB-431542 inhibited growth in colorectal cancer cells over expressing Tgfb1 (PMID: 15967103).",
            "molecularProfile": {
                "id": 6274,
                "profileName": "TGFB1 over exp"
            },
            "therapy": {
                "id": 2712,
                "therapyName": "SB-431542",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2768,
                    "pubMedId": 15967103,
                    "title": "A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15967103"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6274,
            "profileName": "TGFB1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}